IQVIA (NYSE:IQV) Insider Eric Sherbet Sells 5,000 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

IQVIA Price Performance

IQVIA stock opened at $235.09 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.75. The stock has a market cap of $38.70 billion, a price-to-earnings ratio of 29.17, a price-to-earnings-growth ratio of 2.01 and a beta of 1.20. The firm has a 50-day moving average of $194.75 and a two-hundred day moving average of $187.20. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $251.36.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the company posted $2.81 earnings per share. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its board has approved a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of IQV. Ameliora Wealth Management Ltd. purchased a new position in IQVIA in the fourth quarter worth $25,000. Financial Freedom LLC purchased a new stake in shares of IQVIA during the 1st quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA in the 1st quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth $27,000. Finally, Gilpin Wealth Management LLC purchased a new position in IQVIA during the 4th quarter worth $27,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on IQV shares. TD Cowen upped their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Evercore restated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Royal Bank Of Canada upped their price objective on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA News Roundup

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
• Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
• Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
• Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
• Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.